GPX4 and cancer: Since therapy-resistant mesenchymal-high cancers have increased vulnerability to ferroptosis inducers, especially GPx4 inhibitors5,6, and MTDH promotes EMT and treatment resistance, we therefore investigated whether MTDH confers enhanced vulnerability to ferroptosis.